iX Biopharma said it has opened its Entity flagship store on JD Worldwide, JD.com’s cross-border e-commerce platform.

JD Worldwide provides a platform for Chinese consumers to purchase authentic imported products and enables international suppliers to sell directly to Chinese consumers without requiring an established presence in China.

Chinese consumers will have access to the full range of Entity nutraceuticals on the Entity JD Worldwide store. These include leading products


RestoriX® , a nicotinamide supplement which helps to increase levels of NAD+ (nicotinamide adenine dinucleotide) in the body needed for important cellular functions like energy metabolism, to counter the process of ageing and boost energy levels and vitality; and

LumeniX® , a sublingual glutathione wafer. Glutathione is the master antioxidant that helps the body to build stronger immunity to protect against viral infections. LumeniX® offers this, and also promotes skin fairness.

The launch of the JD Worldwide flagship store is the first foray into the Chinese market by Entity, the nutraceuticals division of iX Biopharma.

This is the first time Entity nutraceuticals will be sold directly to Chinese consumers through an external e-commerce platform, marking an exciting milestone for the Group.

Target: Chinese consumers


“China is a high priority market for us. Australian-made health supplements such as Entity are regarded by Chinese consumers as the gold standard of healthcare products due to Australia’s reputation for safety and quality. The launch of our Entity JD Worldwide store will now allow Chinese consumers close and convenient access to our products without having to travel to Australia.”

-- Eva Tan (photo),
Director of Corporate and Commercial Strategy of iX Biopharma

Entity is also preparing a launch of its flagship store on Tmall Global next week.

JD and Tmall are the two largest e-commerce platforms in China, commanding over 85% of the total B2C e-commerce market in China.

Entity nutraceuticals are developed and formulated by Australian scientists and manufactured in the Group’s TGA approved, cGMP-compliant manufacturing facility located in Victoria, Australia.

iX Biopharma said its Entity nutraceuticals are sold in more than 250 pharmacies and health food shops in Sydney, Melbourne and Perth, Australia.

Stock price 

15 c

52-week range

13 – 29 c

Market cap

S$98 m

PE (ttm)


Dividend yield 


1-year return


Shares outstanding

649 m

Source: Bloomberg

Entity nutraceuticals are natural, clinically-supported formulations.

Generic vitamin and mineral supplements that are widely available in the market serve to replenish nutritional deficiencies of a non-ideal diet.

iX Biopharma said Entity nutraceuticals, on the other hand, are designed to produce beneficial and perceptible improvement to a specific condition, and form an important part of a healthcare strategy to prevent more serious diseases.

Entity products are available in Singapore also via its website https://www.entity-health.com/about/

Share Prices

Counter NameLastChange
AEM Holdings4.0000.040
Avi-Tech Electronics0.275-0.005
Broadway Ind0.141-
China Sunsine0.4500.010
Food Empire0.500-0.005
Fortress Minerals0.3500.010
Geo Energy Res0.3650.010
Golden Energy0.7950.045
GSS Energy0.050-
ISDN Holdings0.430-
IX Biopharma0.131-0.001
Jiutian Chemical0.0770.001
KSH Holdings0.335-
Leader Env0.050-
Medtecs Intl0.109-0.001
Meta Health0.0300.003
Moya Asia0.0890.001
Nordic Group0.490-
Oxley Holdings0.159-0.001
REX International0.225-
Sinostar PEC0.180-
Southern Alliance Mining0.630-
Straco Corp.0.410-
Sunpower Group0.260-
The Trendlines0.083-
Totm Technologies0.1230.001
UG Healthcare0.168-0.001
Uni-Asia Group0.860-0.030
Wilmar Intl3.840-0.020
Yangzijiang Shipbldg1.0300.010

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 240 guests and no members online